GlassScriptPhysician profile
Danielle A Otis
NPI 1457708109
$1,763.74
in general payments reported to CMS, 2019-2025
38 companies · $900 in 2025
The $900 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $864 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $208.73 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.94 | 2024 | Calquence |
| Emd Serono, INC. | $140.78 | 2024 | |
| Merck Sharp & Dohme LLC | $117.96 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Takeda Pharmaceuticals U.S.A., INC. | $113.52 | 2024-2025 | Fruzaqla, Iclusig |
| Seagen INC. | $99.99 | 2025 | |
| Pfizer INC. | $84.17 | 2024-2025 | |
| Abbvie INC. | $54.05 | 2024-2025 | |
| Beigene USA, INC. | $53.44 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $48.34 | 2024-2025 | Injectafer, Vanflyta |
| Tersera Therapeutics LLC | $42.87 | 2024-2025 | Zoladex |
| Pharmaessentia USA Corporation | $40.52 | 2024-2025 | Besremi |
| Genzyme Corporation | $35.07 | 2024 | |
| Sirtex Medical INC | $32.52 | 2025 | Sir-Spheres Microspheres |
| Adc Therapeutics America, INC. | $31.15 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $30.45 | 2025 | Rybrevant |
| Progenics Pharmaceuticals, INC. | $29.51 | 2024 | |
| Aveo Pharmaceuticals, INC. | $28.76 | 2024-2025 | |
| Incyte Corporation | $27.81 | 2025 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $27.26 | 2024 | Onivyde |
| Genentech USA, INC. | $26.80 | 2025 | Venclexta |
| Inari Medical, INC. | $26.17 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Beone Medicines USA, INC. | $26.06 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $25.03 | 2024 | Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $23.59 | 2025 | Xpovio |
| Spectrum Pharmaceuticals INC. | $23.43 | 2025 | Rolvedon |
| Agios Pharmaceuticals, INC. | $23.25 | 2024 | Pyrukynd |
| Eisai INC. | $21.52 | 2024 | |
| Sobi, INC | $20.66 | 2024 | |
| Lilly USA, LLC | $20.50 | 2025 | Jaypirca, Verzenio |
| Pharmacosmos Therapeutics INC. | $19.29 | 2024 | Monoferric |
| Stemline Therapeutics INC. | $18.84 | 2025 | Orserdu |
| Invivyd INC | $16.48 | 2025 | Pemgarda |
| Puma Biotechnology, INC. | $15.99 | 2025 | |
| Gilead Sciences, INC. | $14.11 | 2024 | |
| Deciphera Pharmaceuticals INC. | $14.09 | 2024 | Qinlock |
| Celgene Corporation | $13.91 | 2024 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $11.18 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Otis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.